ONCO3ONCOCLÍNICAS DO BRASIL SERVIÇOS MÉDICOS S.A.Company Data · 2T26updated 2026-08-24
1 Overview 4T20 — 2T26 · 23 quarters
ONCOCLÍNICAS DO BRASIL SERVIÇOS MÉDICOS S.A.
ONCO3Serviços médicos

Oncoclínicas do Brasil Serviços Médicos S.A., together with its subsidiaries, provides oncology, hematology, radiotherapy, and genomics healthcare services in Latin America. The company offers treatment services, including radiotherapy, hormone therapy, immunotherapy, port-a-cath, palliative care, target therapy, breast cancer hormone therapy, bone marrow transplant, non-oncological infusions, oral chemotherapy, and prostate cancer hormone therapy; and surgery procedures, such as breast, head and neck, lung, prostate cancer, stomach, bladder cancer, oncological, kidney cancer, gynecological, and testicular cancer. It also provides diagnostics services comprising pathological analysis, genetic testing, molecular journey, personalized medicine and individualized treatment, myelogram-bone marrow biopsy, and ONCO test-PDO. In addition, the company offers treatment support services, which include veinviewer, cryotherapy, integrative medicine, and DeLife, as well as hilotherapy, laser therapy, OC care line, OC precision medicine, OncoACCESS, survivorship, and telemedicine services. Oncoclínicas do Brasil Serviços Médicos S.A. was incorporated in 2010 and is headquartered in São Paulo, Brazil.

SectorServiços médicos
Company HeadquartersSão Paulo, SP
Full Time Employees
CEOMr. Carlos Gil Moreira Ferreira
Listing SegmentNovo Mercado
Foundation2010
Customer Rating
Employee Rating
Estrutura Acionária
67%Free Float
Latache Gestão De Recursos Ltda15%
Josephina Iii Fundo De Investimento Em Participações10%
Brb - Banco De Brasília Sa9%
Free Float67%
Valuation
PriceR$ 1,15
Shares Outstanding1.122.618
Market Capitalization1.291
( - ) Cash & Equivalents145
( + ) Total Debt3.817
( = ) Enterprise Value4.963
P/E32,7x
EV / EBITDA72,1x
R$ 1,15
Adj close · daily
▼ 10,9%
Income Statement
Revenue4.990
EBITDA(2.391)
EBIT(2.685)
Net Income(4.372)
SG&A %(25,6%)
Balance Sheet
Assets6.604
Cash145
Total Debt3.817
Net Debt3.672
Fixed Assets3.586
Working Capital66
Equity98
Invested Capital & Reinvestment
Invested Capital Turnover0,84x
Marginal IC Turnover0,43x
Reinvestment % NOPAT35,7%
Working Capital Turnover10,85x
Cash Conv. Cycle11,2
Fixed Assets Turnover1,29x
D&A % Fixed Assets6,9%
Capex % Revenue2,6%
-59,9 %
RoIC · LTM
RoIC (LTM)
Margins & Returns
Revenue Growth(19,0%)
Gross Margin27,3%
EBITDA Margin(47,9%)
Net Income Margin(87,6%)
Effective Tax Rate(11,5%)
Operating Leverage(30,09x)
RoIC(59,9%)
RoE(586,8%)
Capital Structure
Current Ratio0,44x
Financial Leverage67,23x
Asset Turnover0,70x
Net Debt / EBITDA(1,54x)
Net Debt & Lease / EBITDA(1,72x)
Cash Flow
CFO Conversion(31,9%)
FCFF Yield12,1%
FCFE Yield(9,6%)
Payout Ratio(0,7%)
Dividend Yield1,9%
Interest % FCFF71,1%
Latest CVM filings
  • 2026-08-14reported 2T26
  • 2026-05-14reported 1T26
  • 2026-04-09reported 4T25
  • 2025-11-14reported 3T25
  • 2025-08-14reported 2T25
  • 2025-05-15reported 1T25